137 related articles for article (PubMed ID: 21334774)
1. [Dual time point 18F-FDOPA PET as a tool for characterizing brain tumors].
González-Forero M; Prieto E; Domínguez I; Vigil C; Peñuelas I; Arbizu J
Rev Esp Med Nucl; 2011; 30(2):88-93. PubMed ID: 21334774
[TBL] [Abstract][Full Text] [Related]
2. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
Fueger BJ; Czernin J; Cloughesy T; Silverman DH; Geist CL; Walter MA; Schiepers C; Nghiemphu P; Lai A; Phelps ME; Chen W
J Nucl Med; 2010 Oct; 51(10):1532-8. PubMed ID: 20847166
[TBL] [Abstract][Full Text] [Related]
3. Identify glioma recurrence and treatment effects with triple-tracer PET/CT.
Li C; Yi C; Chen Y; Xi S; Guo C; Yang Q; Wang J; Sai K; Zhang J; Ke C; Chen F; Lv Y; Zhang X; Chen Z
BMC Med Imaging; 2021 May; 21(1):92. PubMed ID: 34059015
[TBL] [Abstract][Full Text] [Related]
4. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.
Chen W; Silverman DH; Delaloye S; Czernin J; Kamdar N; Pope W; Satyamurthy N; Schiepers C; Cloughesy T
J Nucl Med; 2006 Jun; 47(6):904-11. PubMed ID: 16741298
[TBL] [Abstract][Full Text] [Related]
5. 18F-FDOPA kinetics in brain tumors.
Schiepers C; Chen W; Cloughesy T; Dahlbom M; Huang SC
J Nucl Med; 2007 Oct; 48(10):1651-61. PubMed ID: 17873130
[TBL] [Abstract][Full Text] [Related]
6. (18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment.
Lizarraga KJ; Allen-Auerbach M; Czernin J; DeSalles AA; Yong WH; Phelps ME; Chen W
J Nucl Med; 2014 Jan; 55(1):30-6. PubMed ID: 24167081
[TBL] [Abstract][Full Text] [Related]
7. 3,4-dihydroxy-6-[18f]-fluoro-L-phenylalanine positron emission tomography in patients with central motor disorders and in evaluation of brain and other tumors.
Seibyl JP; Chen W; Silverman DH
Semin Nucl Med; 2007 Nov; 37(6):440-50. PubMed ID: 17920351
[TBL] [Abstract][Full Text] [Related]
8. Quantitative analysis of normal and pathologic adrenal glands with 18F-FDOPA PET/CT: focus on pheochromocytomas.
Moreau A; Giraudet AL; Kryza D; Borson-Chazot F; Bournaud C; Mognetti T; Lifante JC; Combemale P; Giammarile F; Houzard C
Nucl Med Commun; 2017 Sep; 38(9):771-779. PubMed ID: 28704339
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas.
Imani F; Agopian VG; Auerbach MS; Walter MA; Imani F; Benz MR; Dumont RA; Lai CK; Czernin JG; Yeh MW
J Nucl Med; 2009 Apr; 50(4):513-9. PubMed ID: 19289420
[TBL] [Abstract][Full Text] [Related]
10. [18F] FDOPA standardized uptake values of brain tumors are not exclusively dependent on LAT1 expression.
Dadone-Montaudié B; Ambrosetti D; Dufour M; Darcourt J; Almairac F; Coyne J; Virolle T; Humbert O; Burel-Vandenbos F
PLoS One; 2017; 12(9):e0184625. PubMed ID: 28937983
[TBL] [Abstract][Full Text] [Related]
11. A high
Isal S; Gauchotte G; Rech F; Blonski M; Planel S; Chawki MB; Karcher G; Marie PY; Taillandier L; Verger A
Br J Radiol; 2018 Apr; 91(1084):20170803. PubMed ID: 29271237
[TBL] [Abstract][Full Text] [Related]
12. [(18)F]FDOPA and [(18)F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease.
Rinne OJ; Nurmi E; Ruottinen HM; Bergman J; Eskola O; Solin O
Synapse; 2001 Jun; 40(3):193-200. PubMed ID: 11304757
[TBL] [Abstract][Full Text] [Related]
13.
Renard D; Collombier L; Laurent-Chabalier S; Mura T; Le Floch A; Fertit HE; Thouvenot E; Guillamo JS
J Neurol; 2021 Apr; 268(4):1266-1275. PubMed ID: 33084938
[TBL] [Abstract][Full Text] [Related]
14. Can (18)F-FDOPA PET/CT predict survival in patients with suspected recurrent glioma? A prospective study.
Karunanithi S; Sharma P; Kumar A; Gupta DK; Khangembam BC; Ballal S; Kumar R; Kumar R; Bal C
Eur J Radiol; 2014 Jan; 83(1):219-25. PubMed ID: 24191944
[TBL] [Abstract][Full Text] [Related]
15. (18)F FDOPA uptake in brain metastasis of breast cancer.
Chiaravalloti A; Floris R; Schillaci O
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):46-7. PubMed ID: 26117270
[No Abstract] [Full Text] [Related]
16. 18F-FDOPA PET for the diagnosis of parkinsonian syndromes.
Darcourt J; Schiazza A; Sapin N; Dufour M; Ouvrier MJ; Benisvy D; Fontana X; Koulibaly PM
Q J Nucl Med Mol Imaging; 2014 Dec; 58(4):355-65. PubMed ID: 25366711
[TBL] [Abstract][Full Text] [Related]
17. The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas.
Taïeb D; Tessonnier L; Sebag F; Niccoli-Sire P; Morange I; Colavolpe C; De Micco C; Barlier A; Palazzo FF; Henry JF; Mundler O
Clin Endocrinol (Oxf); 2008 Oct; 69(4):580-6. PubMed ID: 18394015
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience.
Ledezma CJ; Chen W; Sai V; Freitas B; Cloughesy T; Czernin J; Pope W
Eur J Radiol; 2009 Aug; 71(2):242-8. PubMed ID: 18511228
[TBL] [Abstract][Full Text] [Related]
19. The usefulness of 18F-fluorocholine PET/CT in the detection of recurrence of central nervous system primary neoplasms.
Montes A; Fernández A; Camacho V; de Quintana C; Gallego O; Craven-Bartle J; López D; Molet J; Gómez-Ansón B; Carrió I
Rev Esp Med Nucl Imagen Mol; 2017; 36(4):227-232. PubMed ID: 28219644
[TBL] [Abstract][Full Text] [Related]
20. Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA.
Cropley VL; Fujita M; Bara-Jimenez W; Brown AK; Zhang XY; Sangare J; Herscovitch P; Pike VW; Hallett M; Nathan PJ; Innis RB
Psychiatry Res; 2008 Jul; 163(2):171-82. PubMed ID: 18504119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
